Technology
United States
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Continue Reading on Ars Technica
This article is aggregated from Ars Technica. Click below to read the full story.